In this study, researchers from Harbin Medical University conducted a comprehensive characterization of the tumor microenvironment in APL patients undergoing arsenic trioxide (ATO) therapy using ...
A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...
Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the U.S. and Europe are diagnosed. For many, the road ahead is grim. Despite ...
A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results